Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the safety, tolerability, drug label and effect in subjects with and without insulin resistance.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Healthy male and female subjects with insulin resistance

• Subjects with controlled hypertension and hyperlipidemia

Exclusion Criteria:

• Smokers

• History of drug or alcohol use

• Autonomic dysfunction

• Significant illness or cardiovascular disease

• Immunodeficiency disease

Other protocol-defined inclusion/exclusion criteria may apply